Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The Ghana study will hypothesize that both the multiple dose and single dose of mebendazole
will achieve effective cure rates against hookworm among children and adolescents. This study
is intended to be a pilot study for a planned Phase 3 registration trial of a new drug for
hookworm, tribendimidine.
Phase:
Phase 4
Details
Lead Sponsor:
PATH
Collaborators:
Ghana Health Services HopeXchange Medical Center, Ghana Kintampo Health Research Centre, Ghana Noguchi Memorial Institute for Medical Research Yale University